Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO2) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.
|Number of pages||12|
|Journal||Molecular Imaging and Biology|
|State||Published - Apr 2022|
Bibliographical noteFunding Information:
This publication was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR001998, the American Cancer Society Grant IRG-19-140-31 and by the University of Kentucky Lucille P. Markey Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
© 2021, World Molecular Imaging Society.
- Fluorine-19 (F)
- Perfluorocarbon (PFC)
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cancer Research